En passant

Cardiotoxicity is one of the main adverse effects of the anti-cancer drugs, affecting the completion of treatment and both short-term and long-term quality of life. Cardio-oncology is an emerging medical field involved in prevention, detection, and treatment of cardiovascular effects from cancer therapy.

Our lab, which is part of the European ERA-NET consortium in Cardio-Oncology, combines medicinal chemistry, molecular and cellular biology and pharmacology to address the following objectives:

- 1- to develop new cardioprotective non-peptide agonists of prokineticin receptor 1 (PKR1),

- 2- to discover novel prohibitins ligands and inhibitors of the initiation factor of translation eIF4A for the treatment of heart diseases and cancers,

- 3- to develop of novel diagnostic tools for cardiotoxicity,

- 4- to identify the molecular and cellular mechanisms controlling cardiac myogenesis, neovasculogenesis, and adipogenesis in hearts injured by anticancer drugs (anthracyclines, cisplatin, etc.).

The biological and medicinal chemistry studies are respectively supervised by Dr Canan Nebigil at the Higher School of Biotechnology (ESBS) of Strasbourg, and Dr Laurent Désaubry at Le Bel Institute of the University of Strasbourg.


Dr Canan Nebigil, CNRS Research Director, Laboratoire de Cardio-Oncologie et Chimie Médicinale, Ecole Supérieure de Biotechnologie de Strasbourg, Boulevard Sébastien Brandt, BP10413, 67412 Illkirch CEDEX, France – Phone : (+33) 368 854 756 – email : nebigil@unistra.fr

Dr Laurent Désaubry, CNRS Research Director, Laboratoire de Cardio-Oncologie et Chimie Médicinale, Institut Le Bel  4 rue Blaise Pascal, CS 90032, 67081 Strasbourg, France – Phone : (+33) 368 851 606 – email : desaubry@unistra.fr